Disseminated Intravascular Coagulation (DIC) Market Size, Share & Trends Analysis Report By Symptoms (Bleeding, Blood Clots, Bruising, Drop in Blood Pressure, Shortness of Breath, Confusion, Fever), Treatment (Medicines, Transfusions, Surgery), Diagnosis (Complete Blood Count with Blood Smear Exam, Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Fibrinogen Blood Test, D-dimer), Route of Administration, End-Users, Distribution Channel, By Region, And By Segment Forecasts, 2024-2031.

Report Id: 2573 Pages: 180 Last Updated: 16 July 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Disseminated Intravascular Coagulation (DIC) Market-

By Symptoms

  • Bleeding
  • Blood Clots
  • Bruising
  • Drop in Blood Pressure
  • Shortness of Breath
  • Confusion
  • Fever

Disseminated Intravascular Coagulation (DIC) Market Seg

By Treatment

  • Medicines
  • Transfusions
  • Surgery
  • Others

By Diagnosis

  • Complete Blood Count with Blood Smear Exam
  • Partial Thromboplastin Time (PTT)
  • Prothrombin Time (PT)
  • Fibrinogen Blood Test
  • D-dimer
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End-user

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Disseminated intravascular coagulation (DIC) Market Snapshot

Chapter 4. Global Disseminated intravascular coagulation (DIC) Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Symptoms Estimates & Trend Analysis

5.1. by Symptoms & Market Share, 2019 & 2031

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Symptoms:

5.2.1. Bleeding

5.2.2. Blood Clots

5.2.3. Bruising

5.2.4. Drop in Blood Pressure

5.2.5. Shortness of Breath

5.2.6. Confusion

Chapter 6. Market Segmentation 2: by Distribution Channel Estimates & Trend Analysis

6.1. by Distribution Channel & Market Share, 2019 & 2031

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel:

6.2.1. Hospital Pharmacy

6.2.2. Retail Pharmacy

6.2.3. Online Pharmacy

6.2.4. Others 

Chapter 7. Market Segmentation 3: by Diagnosis Estimates & Trend Analysis

7.1. by Diagnosis & Market Share, 2019 & 2031

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Diagnosis:

7.2.1. Complete Blood Count with Blood Smear Exam

7.2.2. Partial Thromboplastin Time (PTT)

7.2.3. Prothrombin Time (PT)

7.2.4. Fibrinogen Blood Test

7.2.5. D-dimer

7.2.6. Others 

Chapter 8. Market Segmentation 4: by End-User Estimates & Trend Analysis

8.1. by End-User & Market Share, 2019 & 2031

8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-User:

8.2.1. Hospitals

8.2.2. Specialty Clinics

8.2.3. Homecare

8.2.4. Others 

Chapter 9. Market Segmentation 5: by Treatment Estimates & Trend Analysis

9.1. by Treatment & Market Share, 2019 & 2031

9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Treatment:

9.2.1. Medicines

9.2.2. Transfusions

9.2.3. Surgery

9.2.4. Others

Chapter 10. Market Segmentation 6: by Route of Administration Estimates & Trend Analysis

10.1.  by Route of Administration & Market Share, 2019 & 2031

10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Route of Administration:

10.2.1. Oral

10.2.2. Parenteral

10.2.3. Others

Chapter 11. Disseminated intravascular coagulation (DIC) Market Segmentation 7: Regional Estimates & Trend Analysis

11.1. North America

11.1.1. North America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Symptoms, 2023-2031

11.1.2. North America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2023-2031

11.1.3. North America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2023-2031

11.1.4. North America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

11.1.5. North America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2023-2031

11.1.6. North America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2023-2031

11.1.7. North America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

11.2. Europe

11.2.1. Europe Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Symptoms, 2023-2031

11.2.2. Europe Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2023-2031

11.2.3. Europe Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2023-2031

11.2.4. Europe Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

11.2.5. Europe Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2023-2031

11.2.6. Europe Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2023-2031

11.2.7. Europe Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

11.3. Asia Pacific

11.3.1. Asia Pacific Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Symptoms, 2023-2031

11.3.2. Asia Pacific Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2023-2031

11.3.3. Asia-Pacific Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2023-2031

11.3.4. Asia-Pacific Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

11.3.5. Asia-Pacific Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2023-2031

11.3.6. Asia-Pacific Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2023-2031

11.3.7. Asia Pacific Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

11.4. Latin America

11.4.1. Latin America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Symptoms, 2023-2031

11.4.2. Latin America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2023-2031

11.4.3. Latin America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2023-2031

11.4.4. Latin America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

11.4.5. Latin America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2023-2031

11.4.6. Latin America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2023-2031

11.4.7. Latin America Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

11.5. Middle East & Africa

11.5.1. Middle East & Africa Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Symptoms, 2023-2031

11.5.2. Middle East & Africa Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2023-2031

11.5.3. Middle East & Africa Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2023-2031

11.5.4. Middle East & Africa Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2023-2031

11.5.5. Middle East & Africa Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2023-2031

11.5.6. Middle East & Africa Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2023-2031

11.5.7. Middle East & Africa Disseminated intravascular coagulation (DIC) Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

Chapter 12. Competitive Landscape

12.1. Major Mergers and Acquisitions/Strategic Alliances

12.2. Company Profiles

12.2.1. Moderna, Inc.    

12.2.2. Alnylam Pharmaceuticals, Inc.  

12.2.3. Sanofi    

12.2.4. Olix Pharmaceuticals, Inc.  

12.2.5. Glaxosmithkline Plc.   

12.2.6. Benitec Biopharma   

12.2.7. Arbutus Biopharma Corporation  

12.2.8. Silence Therapeutics  

12.2.9. Rexahn Pharmaceuticals, Inc.

12.2.10. Arrowhead Pharmaceuticals, Inc.

12.2.11. Quark    

12.2.12. Dicerna Pharmaceuticals (Novo Nordisk A/S)

12.2.13. Thermo Fisher Scientific Inc  

12.2.14. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
6225
Security Code field cannot be blank!

Frequently Asked Questions

Disseminated Intravascular Coagulation (DIC) Market Size is valued at USD 437.3 Mn in 2023 and is predicted to reach USD 563.8 Mn by the year 2031

Disseminated Intravascular Coagulation (DIC) Market is expected to grow at a 3.3% CAGR during the forecast period for 2024-2031.

GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), Astra

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying